Alumis earnings release, August 13, 2026
Alumis Reports Second Quarter 2026 Financial Results and
Highlights Recent Achievements
– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO – – Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in moderate-to-severe plaque psoriasis (PsO) in Q4 2026 – – Potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE anticipated in Q3 2026 –
SOUTH SAN FRANCISCO, Calif., August 13, 2026 – Alumis Inc.
(Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the quarter ended June 30, 2026, and highlighted recent achievements and upcoming milestones.
“Envudeucitinib’s Phase 3 clinical validation in PsO, reinforced by our ONWARD3 long-term data, demonstrates the power of maximal TYK2 inhibition in IL-23/IL-17-driven diseases, and our anticipated Phase 2b LUMUS readout in SLE may substantiate its role in IFN-driven diseases -- potentially unlocking broader potential of our TYK2 franchise,” said Martin Babler, President and Chief Executive Officer of Alumis. “The ONWARD3 long-term data delivered the highest reported PASI 100 response rate among oral therapies, positioning envudeucitinib to set a new standard in PsO. We remain on track to submit a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 with the goal, if approved, of bringing this new oral treatment option to patients.”
“Looking ahead, our main focus is on realizing our two TYK2 pipeline-in-a-pill franchise opportunities.” Babler added, “Based on the strength of clinical data to date, we are prioritizing Sjögren’s disease and cutaneous lupus erythematosus (CLE) as the next indications for envudeucitinib, subject to our LUMUS results and disciplined capital allocation. We are also advancing A-005, our CNS-penetrant TYK2 inhibitor, into a Phase 2 biomarker trial in Parkinson’s disease patients, planned to be initiated in the first half of 2027. Collectively, these programs underscore our goal to leverage the breadth of the TYK2 mechanism to pursue a broad range of immune-mediated diseases.”
Second Quarter 2026 and Recent Highlights
Envudeucitinib: a next
- generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate
- to
- severe plaque psoriasis
Envudeucitinib: Systemic Lupus Erythematosus (SLE)
TYK2 Franchise and Pipeline Update
Anticipated 2026 Milestones
Second Quarter 2026 Financial Results
Financial Guidance
About Alumis
Alumis is a late-stage biopharmaceutical company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib, formerly known as ESK-001, for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005, its central nervous system penetrant TYK2 inhibitor, with initial development focused on Parkinson’s disease and additional neuroinflammatory, neurodegenerative and peripheral immune-mediated disease indications under evaluation. For more information, visit www.alumis.com or follow us on LinkedIn or X.
Financial statements
Income Statement
Three Months Ended June 30, — (Unaudited) (in thousands)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Revenue: | License revenue | $— | $— | $— | 17,389 |
| Revenue: | Collaboration revenue | 1,662 | 2,666 | 3,403 | 2,666 |
| Revenue: | Total revenue | 1,662 | 2,666 | 3,403 | 20,055 |
| Operating expenses: | Research and development expenses | 85,337 | 108,755 | 166,877 | 205,377 |
| Operating expenses: | General and administrative expenses | 23,356 | 34,450 | 41,966 | 56,745 |
| Operating expenses: | Intangible assets impairment loss | 41,824 | 41,824 | ||
| Operating expenses: | Total operating expenses | 150,517 | 143,205 | 250,667 | 262,122 |
| Operating expenses: | Loss from operations | -148,855 | -140,539 | -247,264 | -242,067 |
| Other income (expense): | Gain on bargain purchase | 187,907 | 187,907 | ||
| Other income (expense): | Interest income | 4,948 | 3,430 | 10,297 | 6,039 |
| Other income (expense): | Other income (expenses), net | -71 | -38 | -64 | -82 |
| Other income (expense): | Total other income (expense), net | 4,877 | 191,299 | 10,233 | 193,864 |
| Other income (expense): | Net income (loss) before income taxes | -143,978 | 50,760 | -237,031 | -48,203 |
| Other income (expense): | Income tax benefit | 1,757 | 8,561 | 1,757 | 8,561 |
| Other income (expense): | Net income (loss) | -142,221 | 59,321 | -235,274 | -39,642 |
| Other comprehensive income (loss): | Unrealized gain (loss) on marketable securities, net | -216 | 30 | -871 | -18 |
| Other comprehensive income (loss): | Total comprehensive income (loss) | -142,437 | 59,351 | -236,145 | -39,660 |
Balance Sheet
December 31, — (Unaudited) (in thousands)
| June 30, – 2026 | December 31, – 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 63,706 | 89,670 |
| Current assets: | Restricted cash | 82 | |
| Current assets: | Marketable securities, current | 438,587 | 218,831 |
| Current assets: | Research and development prepaid expenses | 4,388 | 2,909 |
| Current assets: | Other prepaid expenses and current assets | 7,403 | 6,740 |
| Current assets: | Total current assets | 514,084 | 318,232 |
| Current assets: | Restricted cash, non-current | 1,388 | 1,301 |
| Current assets: | Property and equipment, net | 16,847 | 18,190 |
| Current assets: | Intangible assets | 9,135 | 50,959 |
| Current assets: | Operating lease right-of-use assets, net | 17,270 | 16,971 |
| Current assets: | Other assets, non-current | 1,894 | 6,287 |
| Current assets: | Total assets | 560,618 | 411,940 |
| Current liabilities: | Accounts payable | 12,800 | 10,106 |
| Current liabilities: | Research and development accrued expenses | 35,572 | 34,781 |
| Current liabilities: | Other accrued expenses and current liabilities | 16,370 | 22,303 |
| Current liabilities: | Deferred revenue, current | 6,669 | 1,458 |
| Current liabilities: | Operating lease liabilities, current | 4,822 | 4,670 |
| Current liabilities: | Total current liabilities | 76,233 | 73,318 |
| Current liabilities: | Operating lease liabilities, non-current | 31,605 | 32,244 |
| Current liabilities: | Deferred tax liability | 383 | 2,140 |
| Current liabilities: | Share repurchase liability | 71 | 123 |
| Current liabilities: | Deferred revenue, non-current | 2,611 | |
| Current liabilities: | Other liabilities, non-current | 168 | 207 |
| Current liabilities: | Total liabilities | 108,460 | 110,643 |
| Stockholders’ equity: | Common stock | 12 | 10 |
| Stockholders’ equity: | Additional paid-in capital | 1,589,979 | 1,202,975 |
| Stockholders’ equity: | Accumulated other comprehensive income (loss) | -683 | 188 |
| Stockholders’ equity: | Accumulated deficit | -1,137,150 | -901,876 |
| Stockholders’ equity: | Total stockholders’ equity | 452,158 | 301,297 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 560,618 | 411,940 |
Full release
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "anticipates," "believes," "plans," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. All statements, other than statements of historical facts, including without limitation those regarding the timing of the initiation of clinical trials, including a Phase 1 trial for the Company’s next clinical candidate, the timing and results of clinical data readouts in its ongoing clinical trials, including the Company’s Phase 2b LUMUS trial in systemic lupus erythematosus, as well as long-term and safety data in moderate-to-severe plaque psoriasis (PsO), the timing of the Company’s planned NDA submission with the FDA for envudeucitinib in PsO, the Company’s plans to prioritize Sjögren’s disease and cutaneous lupus erythematosus as additional indications for envudeucitinib, the Company’s goal to bring a new oral treatment option to patients with PsO and pursue a broad range of immune-mediated disease... (truncated)ety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in Alumis’ forward-looking statements. Such risks and uncertainties include, without limitation, those related to Alumis’ ability to advance envudeucitinib or its other programs and to obtain regulatory approval of and ultimately commercialize Alumis’ clinical candidates, the timing, costs, and results of preclinical and clinical trials, Alumis’ ability to fund development activities and achieve development goals, Alumis’ ability to protect its intellectual property and other risks and uncertainties described in Alumis’ filings with the Securities and Exchange Commission (SEC) under the heading “Risk Factors” and elsewhere in such filings and reports, including any future reports Alumis may file with the SEC from time to time. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.